株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

HER2陰性乳癌の世界市場:2015年〜2019年

Global HER2-Negative Breast Cancer Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 341167
出版日 ページ情報 英文 50 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。
Back to Top
HER2陰性乳癌の世界市場:2015年〜2019年 Global HER2-Negative Breast Cancer Market 2015-2019
出版日: 2015年09月30日 ページ情報: 英文 50 Pages
概要

HER2陰性乳癌の世界市場は、2014年から2019年の間、15.94%のCAGRで拡大することが予測されています。

当レポートでは、世界におけるHER2陰性乳癌市場の薬物分子タイプ別、投与経路別、地域別の規模と今後の予測を提供しており、市場の成長要因と課題、主な動向、競合分析などとともにお届けします。

第1章 エグゼクティブサマリー

  • 概況

第2章 当レポートの調査範囲

  • 市場概要
  • 主要ベンダーの製品

第3章 市場調査手法

  • 調査手法
  • 経済指標

第4章 イントロダクション

  • 主な市場概況

第5章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第6章 薬物分子タイプ別の市場分類

  • 生物製剤
  • 小分子

第7章 投与経路別の市場分類

  • 経口
  • 非経口

第8章 地理区分

  • 地域別の市場分類
  • 南北アメリカのHER2陰性乳癌市場
  • 欧州・中東・アフリカ地域のHER2陰性乳癌市場
  • アジア太平洋地域のHER2陰性乳癌市場

第9章 パイプライン・ポートフォリオ

  • パイプラインの最終段階にある候補薬の主要情報

第10章 市場成長因子

第11章 市場成長因子の影響

第12章 市場の課題

第13章 成長因子と課題の影響

第14章 市場動向

第15章 ベンダー情勢

  • 競合シナリオ
  • 主なニュース
  • M&A
  • 市場シェア分析
  • Other and future 有力ベンダー

第16章 主要ベンダーの分析

  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer

第17章 付録

  • 略語リスト

第18章 Technavioについて

目次
Product Code: IRTNTR7383

About HER2-negative breast cancer

HER2-negative breast cancer is a subtype of breast cancer and is the condition when the HER2 is expressed less in the tumor. According to the American Society of Clinical Oncology, most of the patients with breast cancer are known to have HER2-negative breast cancer. HER2-negative breast cancer patients can also be hormone receptor positive (HR+). The HER2 protein is found on the outer surface of the breast cells, and the hormone receptors are found inside breast cells. The cancers that have detectable hormone receptors are known as HR+ breast cancer, and those with HER2-negative have a low level of HER2 gene or the HER2 protein. HER2-negative breast cancer can also be HR+ and then the most preferred therapy is hormone therapy. These patients can be treated with chemotherapy or targeted therapy to improve their condition. It can also be treated with platinum-based drugs, and drugs such as capecitabine, eribulin, gemcitabine, ixabepilone, and vinorelbine. These drugs have several adverse effects on patients as some of them can attack the healthy cells of the body while destroying the malignant cells.

Technavio's analysts forecast the global HER2-negative breast cancer market to grow at a CAGR of 15.94% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global HER2-negative breast cancer market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of HER2-negative breast cancer.

Based on type of drug molecule, the market is segmented as follows:

  • Biologics
  • Small molecules

Based on route of administration, the market is segmented as follows:

  • Oral
  • Parenteral

This report includes a discussion of the market in the following three regions:

  • Americas (the US, Canada, Mexico, and Brazil)
  • EMEA (the UK, Germany, Italy, France, Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE)
  • APAC (Japan, China, Australia, Singapore, South Korea, and India)

Technavio's report, Global HER2-Negative Breast Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, APAC, and EMEA; it also covers the landscape of the global HER2-negative breast cancer market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer

Other Prominent Vendors

  • AbbVie
  • AstraZeneca
  • BioMarin
  • Bristol-Myers Squibb
  • Eisai
  • Eli Lilly
  • Galena Biopharma
  • Incyte
  • Merck
  • Merck Serono
  • Merrimack
  • Nektar
  • Tesaro

Key market driver

  • Significant unmet needs
  • For a full, detailed list, view our report

Key market challenge

  • Premium-priced therapies
  • For a full, detailed list, view our report

Key market trend

  • Emerging therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Market segmentation by type of drug molecule

  • Biologics
  • Small molecules

PART 07: Market segmentation by route of administration

  • Oral
  • Parenteral

PART 08: Geographical segmentation

  • Market segmentation by geography 2014-2019
  • HER2-negative breast cancer market in Americas 2014-2019
  • HER2-negative breast cancer market in EMEA 2014-2019
  • HER2-negative breast cancer market in APAC 2014-2019

PART 09: Pipeline portfolio

  • Key information about late-stage pipeline candidates

PART 10: Market drivers

PART 11: Impact of drivers

PART 12: Market challenges

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape

  • Competitive scenario
  • Key news
  • Mergers and acquisitions
  • Market share analysis
  • Other and future prominent vendors

PART 16: Key vendor analysis

  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer

PART 17: Appendix

  • List of abbreviations

PART 18: EExplore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global HER2-negative breast cancer market 2014-2019 ($ billions)
  • Exhibit 03: Five forces analysis
  • Exhibit 04: Segmentation of global HER2-negative breast cancer market by geography 2014
  • Exhibit 05: HER2-negative breast cancer market in Americas 2014-2019 ($ millions)
  • Exhibit 06: HER2-negative breast cancer market in EMEA 2014-2019 ($ millions)
  • Exhibit 07: HER2-negative breast cancer market in APAC 2014-2019 ($ millions)
  • Exhibit 08: Region-wise comparison of market size 2014-2019 ($ millions)
  • Exhibit 09: Major pipeline drug candidates in phase III stage of development
  • Exhibit 10: Impact of drivers
  • Exhibit 11: Impact of drivers and challenges
  • Exhibit 12: Vendor ranking 2014
  • Exhibit 13: Key takeaways: F. Hoffmann-La Roche
  • Exhibit 14: Novartis: Sales and YoY growth of Afinitor 2012-2014 ($ millions)
  • Exhibit 15: Key takeaways: Novartis
  • Exhibit 16: Key takeaways: Pfizer
  • Exhibit 17: Business segmentation 2013 and 2014 by revenue ($ billions)
  • Exhibit 18: Geographical segmentation by revenue 2014
Back to Top